India: National Digital Database of Domestic Pharma Manufacturers in The Offing
India’s drug regulatory body, Central Drugs Standard Control Organisation (CDSCO), is reportedly creating a national digital database of pharmaceutical manufacturers and their medicines so that regulators can be more effective when acting on problems like drug shortages and quality issues.
According to a report in the Economic Times, CDSCO is finalising software for this and plans to amend rules for drugs and cosmetics to make it mandatory for manufacturers to regularly put details of their facilities and products in this database.
The move is important to understand India’s pharma manufacturing capacity, improve inspections and law enforcement, and ensure patients get better medicines, experts said. Currently, there is no comprehensive, real-time information on medicine makers in India and the central regulatory body relies on data from state authorities for specific queries. Often, states themselves are unaware of which drugs are manufactured in other states.
The new database would maintain names, addresses and licences of all manufacturers, therapeutic categories of their medicines and details like their dosages and forms.
Once implemented, manufacturers will have to upload information of their existing facilities and medicines into the database within three months, after which state authorities would verify it through site visits. Going forward, state regulators will update the database whenever they approve new drugs.
The data will be used for various functions, including taking stock of manufacturers producing Active Pharmaceutical Ingredients (API). This would help improve response time during drug shortages due to reduction in API supply. It could also help create better policies to promote the domestic industry. The database may also be used to restrict manufacture or sale of specific medicines. It will be a part of ‘Sugam’, the e-governance portal of CDSCO.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
24th Pharma Asia International Exhibition & Conferences to Open in Karachi, Pakistan
-
India Launches Concentrated Anti-Dumping Actions Against Eight Categories of Chinese Chemicals, Covering APIs/Intermediates, Polyurethanes, and Refrigerants
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
CPHI & PMEC India 2026
-
8th Annual Pharma Manufacturing and Automation Convention 2026
-
Pharma Manufacturing & Automation Excellence Awards 2026
-
CPHI Korea 2026: A Leading Gateway to Korea’s Pharmaceutical and Biopharma Market
-
Three Major Indian Chemical Investments Target China's PC Exports
-
Pharmaconex
-
India Launches Anti-Dumping Probe into PET Film from China, Singapore, Thailand and the UAE
Recommend Reading
-
GLP-1 API Route to U.S. Abruptly Narrows: FDA Heavily Penalizes U.S. Compounding Pharmacy and Bypasses Warning Letter to Ban Chinese Factory
-
European Gas Breaks €80 Intraday, Putting Chemical and Fertilizer Output Back Under Pressure
-
Lotte Chemical Jumps Nearly 13% as Korean Petrochemical Stocks Rally on Supply-Tightening Bets
-
Ammonia Leaks in Iraq and Jordan Put Fertilizer Production and Port Safety on Alert
-
Huide Technology Partners with U.S. Firm to Open the Door to Mass Production of Circular TPU
-
October Benzene Market Trend Summary (October 1, 2025 - October 31, 2025) in China
-
Business Society’s PET Trend Analysis for September 15, 2026: Anti-Depreciation Early Warning
-
Business Society September 24, 2026 Acrylic Acid Trend Analysis: Weak Rebound
-
Phthalic Anhydride Prices Rebound and Rise in China
-
Business Society September 11, 2026 MIBK Trend Analysis: Clearly Upward